In this review, the authors focus on recent updates on the impact of antibiotic resistance in the cancer setting, particularly on the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.).

Commonly known as drug resistance, this phenomenon is one of the most challenging problems facing cancer researchers and patients today. When cancer cells resist the effects of drugs used for treatment, they can grow and reform tumors, a process known as recurrence or relapse.

We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel...

Drug resistance in cancer comes in two forms: intrinsic resistance and acquired resistance. Intrinsic resistance is present before a therapy is administered, and it results in the inherent ability of cancer cells to survive at clinically relevant concentrations of a drug.

Antibiotics are considered the first line of choice for treating bacterial infections in cancer patients. In this scenario, the rapid emergence of drug-resistant bacteria burdens cancer...